Percutaneous absorption of azelaic acid in humans.
Six healthy male volunteers received a single topical treatment with 5 g of an anti-acne cream containing 20% azelaic acid (AzA) onto the face, the chest and the upper back. One week later 1 g of AzA was given orally to the same subjects as aqueous microcrystalline suspension. Following the two treatments the renal excretion of the unchanged compound was measured. Analysis included ether extraction of the urine, derivatization of extract and HPLC with UV detection. After topical application 2.2 +/- 0.7%, and after oral administration 61.2 +/- 8.8% of the dose had been excreted unchanged with the urine. By comparing both amounts, the percutaneous absorption of AzA from the cream was assessed to 3.6% of the dermally applied dose.
Täuber
U
U
Institute of Pharmacokinetics, Schering AG, Berlin, FRG.
Weiss
C
C
Matthes
H
H
D000042:Absorption; D000279:Administration, Cutaneous; D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D002851:Chromatography, High Pressure Liquid; D003998:Dicarboxylic Acids / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000652:urine; D006801:Humans; D008297:Male; D009994:Osmolar Concentration
D003998:Dicarboxylic Acids; C010038:azelaic acid